The combination therapy provided a high remission rate in previously untreated older and high-risk patients.
An ultra-hypofractionated approach was found noninferior to conventional hypofractionation but was accompanied by more urinary-tract and bowel symptoms.
Cisplatin and S-1 remain the standard, based on phase III trial results.
The PARP inhibitor improved progression-free survival and durable response.
Investigational agent voxelotor significantly increased hemoglobin levels and reduced hemolysis compared with placebo.
Relapse-free survival was significantly improved with S-1 plus docetaxel compared with S-1 alone.
Highlights of new treatments for myeloma and lymphoma
Highlights of the latest treatments
Highlights of new treatments for patients with non–small-cell and small-cell lung cancer
Highlights of the latest treatments for urothelial and prostate cancers
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
The use of rituximab following consolidation therapy and autologous stem cell transplantation significantly improved patient outcomes.
Short-term reductions in agitation were helpful, but other components of delirium need further study.
Adding durvalumab to standard therapy significantly improved outcomes, but longer follow-up is required.
Long-term results confirm that survival is noninferior with sentinel versus axillary dissection.
More intense preoperative chemotherapy fails to improve survival.
The anti-PD-1 agent nivolumab was active in biomarker-defined patients with microsatellite instability-high or DNA mismatch repair-deficient disease.
Women's Health Initiative randomized trial findings suggest lowering dietary fat also lowers mortality after breast cancer.
Treatment was effective for 70% of hemorrhages associated with apixaban or rivaroxaban.
From 1990 through 2013, the percentage of patients with non–small-cell lung cancer who never smoked rose from 8.0% to 14.9%.
Palbociclib demonstrated activity in early-stage disease resistant to endocrine therapy, but prolonged exposure may be required.